Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy

CONCLUSIONS: Among patients with IgA nephropathy, treatment with iptacopan resulted in a significant and clinically meaningful reduction in proteinuria as compared with placebo. (Funded by Novartis; APPLAUSE-IgAN ClinicalTrials.gov number, …